Literature DB >> 17852075

Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis.

Lene S Knudsen1, Ib J Christensen, Tine Lottenburger, Mads N Svendsen, Hans J Nielsen, Lone Nielsen, Kim Hørslev-Petersen, Jens E B Jensen, Gina Kollerup, Julia S Johansen.   

Abstract

Interleukin (IL)-6, a key player in the inflammatory response, may be a useful biomarker in rheumatoid arthritis (RA). The aim was to determine analytical variability, a reference interval in healthy subjects, and long- and short-term variation in serum and plasma IL-6 in healthy subjects and RA patients. An enzyme-linked immunosorbent assay from R&D was used for determination of serum and plasma IL-6. The IL-6 concentration did not depend on the type of anticoagulant used or the 3-h time delay between sampling and processing or repeated freeze-thaw cycles. The median plasma and serum IL-6 in 318 healthy subjects were 1.3 pg ml(-1) (range 0.33-26) and 1.4 pg ml(-1) (range 0.25-23), respectively. The median coefficient of variation in plasma IL-6 in 27 healthy subjects during 1 month, and repeated after 6 and 12 months were 27%, 31% and 26%, respectively. No significant long-term changes were observed in serum IL-6 over a 3-year period (14%, p = 0.33). Exercise (cycling) increased serum IL-6 in healthy subjects but not in RA patients. In conclusion, circulating IL-6 is stable regarding sample handling and shows little variation over time. Changes in IL-6 concentrations > 60% (2 times the biological variation) are likely to reflect changes in disease activity and not only pre-analytical or normal biological variability.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17852075     DOI: 10.1080/13547500701615017

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  37 in total

1.  Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma.

Authors:  Alex Reza Gholiha; Peter Hollander; Ingrid Glimelius; Gustaf Hedstrom; Daniel Molin; Henrik Hjalgrim; Karin E Smedby; Jamileh Hashemi; Rose-Marie Amini; Gunilla Enblad
Journal:  Blood Adv       Date:  2021-03-23

Review 2.  Non-invasive, ultra-sensitive, high-throughput assays to quantify rare biomarkers in the blood.

Authors:  Jaclyn A Freudenberg; Kathryn Bembas; Mark I Greene; Hongtao Zhang
Journal:  Methods       Date:  2008-06-23       Impact factor: 3.608

Review 3.  Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.

Authors:  Giovanni Lombardi; Mosè Barbaro; Massimo Locatelli; Giuseppe Banfi
Journal:  Endocrine       Date:  2017-02-08       Impact factor: 3.633

4.  The reliability of the IL-6, sIL-6R and sgp130 response to a preloaded time trial.

Authors:  I Walshe; P Robson-Ansley; A St Clair Gibson; C Lawrence; K G Thompson; L Ansley
Journal:  Eur J Appl Physiol       Date:  2010-06-24       Impact factor: 3.078

Review 5.  Measuring myokines with cardiovascular functions: pre-analytical variables affecting the analytical output.

Authors:  Giovanni Lombardi; Veronica Sansoni; Giuseppe Banfi
Journal:  Ann Transl Med       Date:  2017-08

6.  Self-rated health and interleukin-6: Longitudinal relationships in older adults.

Authors:  Filip K Arnberg; Mats Lekander; Jennifer N Morey; Suzanne C Segerstrom
Journal:  Brain Behav Immun       Date:  2016-02-09       Impact factor: 7.217

7.  Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6.

Authors:  Xiling Jiang; Yanli Zhuang; Zhenhua Xu; Weirong Wang; Honghui Zhou
Journal:  AAPS J       Date:  2016-03-09       Impact factor: 4.009

8.  Depressive symptoms are associated with allostatic load among community-dwelling older adults.

Authors:  Roni W Kobrosly; Edwin van Wijngaarden; Christopher L Seplaki; Deborah A Cory-Slechta; Jan Moynihan
Journal:  Physiol Behav       Date:  2014-01-17

9.  Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma.

Authors:  Robert J Biggar; Julia S Johansen; Karin Ekström Smedby; Klaus Rostgaard; Ellen T Chang; Hans-Olov Adami; Bengt Glimelius; Daniel Molin; Stephen Hamilton-Dutoit; Mads Melbye; Henrik Hjalgrim
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

10.  The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients.

Authors:  Soo-Jin Chung; Yong-Jin Kwon; Min-Chan Park; Yong-Beom Park; Soo-Kon Lee
Journal:  Yonsei Med J       Date:  2011-01       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.